Kidney Disease News and Research

RSS

All Canadian provinces except Quebec announce funding agreement for PNH drug, Soliris

L'Association Québécoise de l'HPN regrets that Quebec remains one of the only jurisdictions in the developed world to decline including the only effective life-saving treatment against an ultra-rare blood disease - paroxysmal nocturnal hemoglobinuria (PNH) - on its public drug insurance plan drugs list.

28 Jul 2011

Reprogrammed kidney cells could make transplants and dialysis things of the past

Approximately 60 million people across the globe have chronic kidney disease (CKD), and many will need dialysis or a transplant. Breakthrough research published in the Journal of the American Society Nephrology indicates that patients' own kidney cells can be gathered and reprogrammed.

28 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

New preclinical data from Baxter's BAX 499 hemophilia study presented at ISTH

Baxter International Inc. announced today that new data from a series of studies on BAX 499, an investigational compound for potential subcutaneous hemophilia therapy, were presented this week during the 23rd annual congress of the International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan.

From Baxter International Inc. 27 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

PNH patients applaud pan-Canadian approach to providing equitable access to Soliris

The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.

25 Jul 2011

Diabetes trends in Alberta

The Alberta Diabetes Surveillance System was created in 2006 in partnership between Alberta Health and Wellness and the Institute of Health Economics. Led by Jeff Johnson in the University of Alberta's School of Public Health, the group has been identifying trends in diabetes, its associated health conditions and monitoring trends in accessing health-care services and has published a comprehensive report called a Diabetes Atlas every two years.

21 Jul 2011

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million.

21 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

U.S. News & World Report ranks UT Southwestern as best hospital in Dallas-Fort Worth region

For the second year in a row, UT Southwestern Medical Center is the top-ranked hospital in the Dallas-Fort Worth region, according to U.S. News & World Report's annual ranking of the nation's best hospitals.

19 Jul 2011

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

The Influenza Specialist Group (ISG) is today warning that high rates of influenza outbreaks have been confirmed in QLD, SA and NSW, but there is still time for most Australians, especially those in at-risk groups, to protect themselves and those around them.

18 Jul 2011

Teva, Amgen settle G-CSF patent litigation

Amgen announced today that the United States (U.S.) District Court in Pennsylvania has entered final judgment and a permanent injunction against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA prohibiting them from infringing Amgen's patents relating to human G-CSF and methods for its use.

16 Jul 2011

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen today announced that the European Commission (EC) has granted marketing authorization for XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors.

15 Jul 2011

DaVita's catheter-reduction program lowers CVC rates in hemodialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), today announced that the company has made landmark progress in reducing "Day 90+" patient central venous catheter (CVC) rates, further cementing its position as the industry leader among large dialysis organizations in catheter reductions through the placement of permanent accesses.

14 Jul 2011

FDA approves protocol for Medtronic's SYMPLICITY HTN-3 for treatment of hypertension

Medtronic, Inc., announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the company's U.S. clinical trial of renal denervation with the Symplicity Catheter System for the treatment of resistant hypertension, an especially dangerous disease affecting hundreds of millions of people worldwide.

From Medtronic 12 Jul 2011

Cardiology study looks at sodium and potassium in diet

A new study suggests that in addition to cutting the amount of sodium in their diets to improve heart health, Americans should also increase consumption of a key mineral found in many fruits and vegetables, potassium.

11 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).

From Baxter International Inc. 8 Jul 2011

ASN President discusses latest information about diabetic nephropathy at ADA

ASN President Dr. Joseph V. Bonventre, MD, PhD, spoke at the American Diabetes Association's annual meeting, 71st Scientific Session, this June in San Diego. Dr. Bonventre was featured at a symposium entitled "New Concepts in Diagnosing and Treating Diabetic Nephropathy."

6 Jul 2011